[go: up one dir, main page]

WO2003026564A3 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO2003026564A3
WO2003026564A3 PCT/SE2002/001748 SE0201748W WO03026564A3 WO 2003026564 A3 WO2003026564 A3 WO 2003026564A3 SE 0201748 W SE0201748 W SE 0201748W WO 03026564 A3 WO03026564 A3 WO 03026564A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutically acceptable
precursors
mammal
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2002/001748
Other languages
English (en)
Other versions
WO2003026564A2 (fr
WO2003026564A9 (fr
Inventor
Stephen P Arneric
Per-Olof Andersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,556 external-priority patent/US20030060513A1/en
Priority to JP2003530203A priority Critical patent/JP2005503424A/ja
Priority to KR10-2004-7004529A priority patent/KR20040039436A/ko
Priority to CA002461731A priority patent/CA2461731A1/fr
Priority to IL16085202A priority patent/IL160852A0/xx
Priority to EP02775633A priority patent/EP1438035A2/fr
Application filed by Pharmacia AB filed Critical Pharmacia AB
Priority to MXPA04002496A priority patent/MXPA04002496A/es
Priority to BR0212824-1A priority patent/BR0212824A/pt
Publication of WO2003026564A2 publication Critical patent/WO2003026564A2/fr
Publication of WO2003026564A3 publication Critical patent/WO2003026564A3/fr
Anticipated expiration legal-status Critical
Publication of WO2003026564A9 publication Critical patent/WO2003026564A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le domaine de l'urologie. L'invention concerne également une nouvelle composition pharmaceutique comprenant une combinaison pharmaceutiquement efficace {i) d'un premier composé sélectionné dans le groupe constitué par des antagonistes du récepteur muscarinique, des inhibiteurs de 5α-réductase, des antagonistes du récepteur α-adrénergique et des précurseurs et de sels de ceux-ci pharmaceutiquement acceptables; et {ii) d'un second composé sélectionné dans le groupe constitué par des agonistes et des antagonistes du récepteur 5-HTla, des précurseurs et des sels de ceux-ci pharmaceutiquement acceptables, et un éventuellement un transporteur ou un diluant de ceux-ci pharmaceutiquement acceptables. L'invention concerne enfin une méthode de traitement thérapeutique de troubles urinaires chez un mammifère, consistant à administrer audit mammifère (notamment à l'homme) nécessitant un tel traitement, une quantité thérapeutiquement efficace d'une composition préparée selon l'invention.
PCT/SE2002/001748 2001-09-27 2002-09-26 Composition pharmaceutique Ceased WO2003026564A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0212824-1A BR0212824A (pt) 2001-09-27 2002-09-26 Composição farmacêutica
KR10-2004-7004529A KR20040039436A (ko) 2001-09-27 2002-09-26 약학 조성물
CA002461731A CA2461731A1 (fr) 2001-09-27 2002-09-26 Composition pharmaceutique pour le traitement des troubles urinaires
IL16085202A IL160852A0 (en) 2001-09-27 2002-09-26 Pharmaceutical compositions for the treatment of urinary disorders
EP02775633A EP1438035A2 (fr) 2001-09-27 2002-09-26 Compositions pharmaceutiques pour le traitement de troubles urinaires
JP2003530203A JP2005503424A (ja) 2001-09-27 2002-09-26 尿疾患の治療用医薬組成物
MXPA04002496A MXPA04002496A (es) 2001-09-27 2002-09-26 Composicion farmaceutica para el tratamiento de enfermedades urinarias.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/965,556 US20030060513A1 (en) 2001-09-27 2001-09-27 Pharmaceutical composition
US09/965,556 2001-09-27
SE0103858-7 2001-11-20
SE0103858A SE0103858D0 (sv) 2001-09-27 2001-11-20 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
WO2003026564A2 WO2003026564A2 (fr) 2003-04-03
WO2003026564A3 true WO2003026564A3 (fr) 2003-12-11
WO2003026564A9 WO2003026564A9 (fr) 2004-06-17

Family

ID=26655594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/001748 Ceased WO2003026564A2 (fr) 2001-09-27 2002-09-26 Composition pharmaceutique

Country Status (9)

Country Link
EP (1) EP1438035A2 (fr)
JP (1) JP2005503424A (fr)
KR (1) KR20040039436A (fr)
CN (1) CN1558756A (fr)
BR (1) BR0212824A (fr)
CA (1) CA2461731A1 (fr)
IL (1) IL160852A0 (fr)
MX (1) MXPA04002496A (fr)
WO (1) WO2003026564A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
FR2843303B1 (fr) * 2002-08-07 2006-01-21 R & D Pharma Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
WO2009151613A1 (fr) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Dérivés d’oxybutynine
WO2010053068A1 (fr) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 Nouvel agent thérapeutique utile pour un symptôme du tractus urinaire inférieur
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955919A1 (fr) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Procédés de traitement des troubles de l'anxiété, des troubles de la céphalée et des troubles de l'alimentation au moyen de psilocybine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005817A1 (fr) * 1994-08-23 1996-02-29 Medinnova Sf Medicament destine au traitement ou a la prophylaxie de l'incontinence
WO1997031637A1 (fr) * 1996-02-28 1997-09-04 Recordati S.A., Chemical And Pharmaceutical Company Utilisation d'antagonistes des recepteurs 5-ht1a pour le traitement de l'incontinence urinaire
WO1999021563A1 (fr) * 1997-10-28 1999-05-06 Merck & Co., Inc. Prevention de retention urinaire aigue precipitee
EP0930298A1 (fr) * 1996-08-01 1999-07-21 Banyu Pharmaceutical Co., Ltd. Derives de piperidine fluores a disubstitution en position 1,4
WO2001021167A1 (fr) * 1999-09-22 2001-03-29 Merck & Co., Inc. Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement
WO2001029022A1 (fr) * 1999-10-18 2001-04-26 Recordati Industria Chimica E Farmaceutica Spa Derives de benzopyrane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005817A1 (fr) * 1994-08-23 1996-02-29 Medinnova Sf Medicament destine au traitement ou a la prophylaxie de l'incontinence
WO1997031637A1 (fr) * 1996-02-28 1997-09-04 Recordati S.A., Chemical And Pharmaceutical Company Utilisation d'antagonistes des recepteurs 5-ht1a pour le traitement de l'incontinence urinaire
EP0930298A1 (fr) * 1996-08-01 1999-07-21 Banyu Pharmaceutical Co., Ltd. Derives de piperidine fluores a disubstitution en position 1,4
WO1999021563A1 (fr) * 1997-10-28 1999-05-06 Merck & Co., Inc. Prevention de retention urinaire aigue precipitee
WO2001021167A1 (fr) * 1999-09-22 2001-03-29 Merck & Co., Inc. Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement
WO2001029022A1 (fr) * 1999-10-18 2001-04-26 Recordati Industria Chimica E Farmaceutica Spa Derives de benzopyrane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DMOCHOWSKI ROGER R. ET AL.: "Advancements in pharmacologic management of the overactive bladder", UROLOGY, vol. 56, no. SUPPL. 6A, 2000, pages 41 - 49, XP002199635 *
WALLIS ROBERT M. ET AL.: "Muscarinic antagonists in development for disorders of smooth muscle function", LIFE SCIENCES, vol. 64, no. 6/7, 1999, pages 395 - 401, XP000972297 *

Also Published As

Publication number Publication date
JP2005503424A (ja) 2005-02-03
BR0212824A (pt) 2004-10-13
EP1438035A2 (fr) 2004-07-21
WO2003026564A2 (fr) 2003-04-03
WO2003026564A9 (fr) 2004-06-17
CA2461731A1 (fr) 2003-04-03
KR20040039436A (ko) 2004-05-10
MXPA04002496A (es) 2004-05-31
IL160852A0 (en) 2004-08-31
CN1558756A (zh) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2003037271A3 (fr) Composes, compositions pharmaceutiques et methodes d'utilisation
CA2335012A1 (fr) Compositions pharmaceutiques de prevention et de traitement de troubles du systeme nerveux central
WO2002060392A3 (fr) Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
MA30412B1 (fr) Composés Pharmaceutiques
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY133564A (en) Compositions and methods for treating osteoporosis and lowering cholesterol
WO2005063745A8 (fr) Nouveaux composes de spiroindoline ou de spiroisoquinoline, methodes d'utilisation et compositions associees
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
WO2000076984A3 (fr) Nouveaux composes, et utilisation et preparation de ces derniers
EP1201268A3 (fr) Compositions pharmaceutiques contenant des antagonistes du récepteur D4 de dopamine et des inhibiteurs de l' Acetylcholinesterase
AU2003228674A1 (en) Muscarinic antagonists
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
RU2001133004A (ru) Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
WO2003026564A3 (fr) Composition pharmaceutique
WO2002100818A3 (fr) Aminediols pour le traitement de la maladie d'alzheimer
HK1044483A1 (zh) Il-8受体拮抗剂
SE0103858D0 (sv) Pharmaceutical composition
AU2002364953A1 (en) Topoisomerase poison agents
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
CA2364178A1 (fr) N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine
WO2004044174A3 (fr) Agents ciblant les topoisomerases
EP2140862A3 (fr) Utilisation d'antagonistes du recepteur GAL3 dans le traitement de la dépression et/ou de l'anxiété et composés utiles dans de telles méthodes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160852

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002496

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002341479

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003530203

Country of ref document: JP

Ref document number: 2461731

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002775633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/02362

Country of ref document: ZA

Ref document number: 200402362

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20028188764

Country of ref document: CN

Ref document number: 1020047004529

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 532121

Country of ref document: NZ

COP Corrected version of pamphlet

Free format text: PAGE 7, DESCRIPTION, ADDED

WWP Wipo information: published in national office

Ref document number: 2002775633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500363

Country of ref document: PH

WWW Wipo information: withdrawn in national office

Ref document number: 2002775633

Country of ref document: EP